Category:Antibody-Drug Conjugates and other protein-drug conjugates
Introduction
Antibody-Drug Conjugates (ADCs) and other protein-drug conjugates represent a novel class of therapeutic agents in cancer treatment. These sophisticated therapies combine the specificity of antibodies or other proteins, which target specific markers on cancer cells, with potent cytotoxic drugs. This selective approach aims to minimize damage to healthy tissues while delivering powerful cancer-fighting agents directly to tumor cells.
ADCs and similar conjugates have shown promise in treating various cancers, including glioblastoma, by targeting unique cellular markers such as EGFR or IL-4R, which are often overexpressed in tumor cells. These treatments are part of an evolving landscape of precision oncology, offering hope for improved outcomes and reduced side effects compared to traditional chemotherapy.
This category page lists some of the groundbreaking ADCs and protein-drug conjugates currently under investigation or in clinical trials for glioblastoma and other malignancies, highlighting their mechanisms, efficacy, and potential in cancer therapy.
List of Treatments
| Drug Name | Common Side Effects | Overall Survival without PBT | Overall Survival with PBT | Progression-Free Survival without PBT | Progression-Free Survival with PBT | Usefulness Rating | Toxicity Level | Toxicity Explanation | |
|---|---|---|---|---|---|---|---|---|---|
| ABT-414 | ABT-414 | Not specified | Not reached at a median follow-up of 5.8 months | Not specified | 6.1 months for all patients, 5.9 months for EGFR amplified patients | 2 | 4 | The drug ABT-414 is in phase 1 of its clinical trials. It demonstrates a tendency towards eye toxicities, especially causing blurred vision. This is an indication of potentially high toxicity. However, due to small sample size and other variables in the study, the evaluations should be taken with caution. It is advised to expect a higher level of toxicity until tested further in next clinical trial phases. | |
| MDNA55 | MDNA55 | Not specified | Not specified in the provided text | Not specified | Not specified in the provided text | 3 | 2.5 | The treatment, MDNA55, is in its early phase of trials, meaning that its potential side effects are still being evaluated. Currently, it's not fully approved by the FDA and exact toxicity is not specified. However, MDNA55 is designed to target cells common in tumor tissue, creating a high potential for effectiveness with fewer harmful effects on healthy tissue. It has shown significant positive response rates, suggesting a manageable toxicity profile. Nevertheless, every treatment carries some risk, and potential side effects might still be discovered. The toxicity rating of 2.5 out of 5 indicates a moderate risk of toxic side effects at this point in time. |
Notes
- The information listed on this page is based on the latest available data from clinical trials and research studies.
- The Usefulness Rating is a subjective evaluation based on the current evidence and trial results.
- Please consult with healthcare professionals for more detailed information and before making any treatment decisions.
